Clinical Trial Update: The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Tekturna (aliskiren) on endothelial function and endothelial progenitor cells in early atherosclerosis was terminated. Results were pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Endothelial Dysfunction

Drugs mentioned

• Tekturna (aliskiren)

Snippet

Sponsor: Mayo Clinic | Conditions: Endothelial Dysfunction | Phase 3 | Status: TERMINATED | Results posted: 2013-02-13